Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* both male and female who are over 19-year-old~* patient whose pain scale is 4\~9~* patient who has pain of mononeuropathy~Exclusion Criteria:~* patient whose CCr is \<60ml/min~* patient who has other pain which is not from mononeuropathy~* patient who is going to have an operation during this study~* patient who has abnormal ECG

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLA5PR GLARS-NF1 & Pregabalin placebo (Type: EXPERIMENTAL): GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
- GLA5PR GLARS-NF1 placebo & Pregabalin (Type: ACTIVE_COMPARATOR): GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).